Whole-body hyperthermia and lonidamine as adjuvant therapy to treatment with cisplatin with or without local radiation in mouse bearing the Lewis lung carcinoma

References

• Baba H., Siddik Z. H., Strebel F. R., Jenkins G. N., Bull J. M. D. Increased therapeutic gain of combined cis-diamminedichloroplatinum(II) and whole body hyperthermia by optimal heat/drug scheduling. Cancer Research 1989; 39: 7041–7044
   Google Scholar
• Baba H., Stephens L. C., Strebel F. R., Siddik Z. H., Newman R. A., Ohno S., Bull J. M. C. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia. Cancer Research 1991; 51: 3568–3577
   PubMed Web of Science ®Google Scholar
• Buccheri G., Ferrigno D., Rosso A. A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer. Cancer 1993; 72: 1564–1572
   PubMed Web of Science ®Google Scholar
• Bull J. M. C., Strebel F. R., Sunderland B. A., Bulger R. E., Edwards M., Siddik Z. H., Newman R. H. O-β-hyroxyethyl-rustoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment. Cancer Research 1988; 48: 2239–2244
   PubMed Web of Science ®Google Scholar
• Calabresi F., Marolla P., Di Lauro L., Gallo Curcio C., Paoletti G., Lombardi A., Giannarelli D., Ballatore P., Foggi C. M., Di Palma M., Stolfi R., Cortesi E. Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study. International Journal of Oncology 1994; 4: 753
   Web of Science ®Google Scholar
• Caputo A., Silvestrini B. Lonidamine, a new approach to cancer therapy. Oncology 1984; 41: 2–6
   PubMed Web of Science ®Google Scholar
• Dahl O., Mella O. The effect of timing and sequence of hyperthermia and cyclophosphamide on a neurogenic rat tumor (BT4A) in vivo. Cancer 1983; 52: 983
   PubMed Web of Science ®Google Scholar
• De Lena M., De Mitrio A., Catino A., Lorusso V., Brandi M. Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results. International Journal of Oncology 1994; 4: 779–782
   Web of Science ®Google Scholar
• DeMartino C., Battelli T., Paggi M. G. Effects of lonidamine on murine and human tumor cells in vitro. Oncology 1984; 41: 15–29
   PubMed Web of Science ®Google Scholar
• DeMartino C., Malorni W., Accinni L. Cell membrane changes induced by lonidamine in human erythrocytes and T lymphocytes, and Ehrlich ascites tumor cells. Experiments in Molecular Pathology 1987; 46: 15–30
   PubMed Web of Science ®Google Scholar
• Dogliotti L., Berruit A., Buniva T., Zola P., Bau M. G., Farris A., Sarobba M. G., Bottini A., Alquati P., Deltetto F., Gosso P., Monzeglio C., Moro G., Sussio M., Perroni D. A randomized comparison of high dose epirubicin versus high dose epirubicin plus lonidamine in advanced breast cancer patients. First results from a cooperative group study. International Journal of Oncology 1994; 4: 747–752
   Web of Science ®Google Scholar
• Fisher G. A., Hahn G. M. Enhancement of cis-platinum (II) diamminedichloride cytotoxicity by hyperthermia. NCI Monograph 1982; 61: 255–258
   Google Scholar
• Floridi A., Bagnato A., Bianchi C. Kinetics of inhibition of mitochondrial respiration by antineoplastic agent lonidamine. Journal of Experimental and Clinical Cancer Research 1986; 5: 273–280
   Web of Science ®Google Scholar
• Floridi A., Lehninger A. L. Action of the antitumor and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Archives of Biochemistry and Biophysics 1983; 226: 73–83
   PubMed Web of Science ®Google Scholar
• Floridi A., Paggi M. G., D'Atri S. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Research 1981a; 41: 4661–4666
   PubMed Web of Science ®Google Scholar
• Floridi A., Paggi M. G., Marcante M. L. Lonidamine a selective inhibitor of aerobic glycolysis of murine tumor cells. Journal of the National Cancer Institute 1981b; 66: 497–499
   PubMed Web of Science ®Google Scholar
• Germani C., Barcellona P. S., Silvestrini B. 1-Halobenzyl-1H-indazole-3-carboxylic acids. A new class of antispermatogenic agents. Journal of Medical Chemistry 1976; 19: 778–782
   PubMed Web of Science ®Google Scholar
• Hahn G. M., vanKersen I., Silvestrini B. Inhibition of the recovery from potentially lethal damage of lonidamine. British Journal of Cancer 1984; 50: 657–660
   PubMed Web of Science ®Google Scholar
• Herman T. S., Teicher B. A. Sequencing of trimodality therapy [cis-diamminedichloro-platinum(II)/hyperthermia/radiation] as determined by tumor growth delay and tumor cell survival in the FSaIIC fibrosarcoma. Cancer Research 1988; 48: 2693–2697
   PubMed Web of Science ®Google Scholar
• Herman T. S., Teicher B. A., Holden S. A., Pfeffer M. R., Jones S. M. Addition of 2-nitroimidazole radiosensitizers to trimodality therapy (cis-diamminedichloroplatinum II/hyperthermia/radiation) in the marine FSaIIC fibrosarcoma. Cancer Research 1990; 50: 2734–2740
   PubMed Web of Science ®Google Scholar
• Kim J. H., Alfieri A., Kim S. H. Radiosensitization of Meth-A fibrosarcoma in mice by lonidamine. Oncology 1984; 41: 36–38
   PubMed Web of Science ®Google Scholar
• Kim J. H., Alfieri A. A., Kim S. H. Potentiation of radiation effects on two murine tumors by lonidamine. Cancer Research 1986; 46: 1120–1123
   PubMed Web of Science ®Google Scholar
• Lorusso V., Catino A., Brandi M., Piano A., Palomba G., Forcignano R., Mazzotta S., Musca F., Serravezza G., Durini E., Contillo A., Pezzella G., Palazzo S., Chetrí C., De Lena M. Cyclophosphamide, mitoxantrone and fluorouracil versus cyclophosphamide, mitox-antrone and fluorouracil plus lonidamine for the treatment of advanced breast cancer. A multicentric randomized clinical trial. International Journal of Oncology 1994; 4: 767–772
   Web of Science ®Google Scholar
• Magno L., Terraneo F., Bertoni F., Tordiglione M., Bardelli D., Rosignolo M. T., Battista Ciotolli G. Double-blind randomized study of lonidamine and radiotherapy in head and neck cancer. International Journal of Radiation Oncology, Biology and Physics 1994; 29: 45–55
   PubMed Web of Science ®Google Scholar
• Mella O., Dahl O. Timing of combined hyperthermia and 1,3-cis(2-chloroethyl)-1-nitro-sourea or cis-diamminedichloroplatinum in BD IX rats with BT4A tumors. Anticancer Research 1985; 5: 259–263
   PubMed Web of Science ®Google Scholar
• Mella O., Eriksen R., Dahl O., Laerum O. D. Acute systemic toxicity of combined cis-diamminedichloroplatinum and hyperthermia in the rat. European Journal of Cancer and Clinical Oncology 1987; 23: 365–373
   PubMedGoogle Scholar
• Nanni O., Lombardi A., Milandri C., Ferrari M., De Matteis A., Mustacchi G., Cariello S., Mascia V., Santoro A., Amadori D. Lonidamine in modulation of response to adriamycin in advanced breast cancer. International Journal of Oncology 1994; 4: 741–746
   Web of Science ®Google Scholar
• Pacini P., Algeri R., Rinaldini M., Guarnieri A., Bastiani P., Barsanti G., Neri B., Marzano S., Tucci E. FEC (fluorouracil, epirubicin and cyclophosphamide) versus EM (epirubicin and mitomycin-C) with or without lonidamine as first line treatment for advanced breast cancer. A multicentric randomized study. Preliminary report. International Journal of Cancer 1994; 4: 761–766
   Google Scholar
• Robins H. I., Cohen J. D., Schmitt C. L., Tutsch K. D., Feierabend C., Arzoomanian R. Z., Alberti D., D'Oleire F., Longo W., Heiss C. Phase I clinical trial of carboplatin and 41·8 degrees C whole-body hyperthermia in cancer patients. Journal of Clinical Oncology 1993; 11: 1787–1794
   PubMed Web of Science ®Google Scholar
• Robins H. I., Longo W. L., Lagoni R. K., Neville A. J., Hugander A., Schmitt C. L., Riggs C. Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. Cancer Research 1988a; 48: 6587–6592
   PubMed Web of Science ®Google Scholar
• Robins H. I., Longo W. L., Steeves R. A., Cohen J. D., Schmitt C. L., Neville A. J., O'Keefe S., Lagoni R. K., Riggs C. Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations. International Journal of Radiation Oncology, Biology and Physics 1990; 18: 909–920
   PubMed Web of Science ®Google Scholar
• Robins H. I., Steeves R. A., Schmitt C. L., Peterson C., Martin P. A. A hyperthermia study of differential sensitivity and thermotolerance in AKR murine leukemia and normal bone marrow cells. International Journal of Radiation Oncology, Biology and Physics 1988b; 14: 979–982
   PubMed Web of Science ®Google Scholar
• Rosbe K. W., Brann T. W., Holden S. A. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemotherapy and Pharmacology 1989; 25: 32–36
   PubMed Web of Science ®Google Scholar
• Savini S., Zoli W., Nanni O., Volpi A., Frassineti G. L., Magni E., Flamigni A., Amadori A., Amadori D. In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. Breast Cancer Research Treatment 1992; 24: 27–34
   PubMed Web of Science ®Google Scholar
• Schabel F. M., Jr, Griswold D. P., Jr, Corbett T. H., Laster W. R., Jr, Mayo J. G., Lloyd H. H. Testing therapeutic hypotheses in mice and man: observations on the therapeutic activity against advanced solid tumors of Man. Methods of Cancer Research 1979; 17: 3–51
   Google Scholar
• Shipley W. V., Stanley J. A., Steel G. G. Tumor size dependence in the radiation response of the Lewis lung carcinoma. Cancer Research 1975; 35: 2488–2493
   PubMed Web of Science ®Google Scholar
• Stanley J. A., Shipley W. V., Steel G. A. Influence of tumor size of hypoxic fraction and therapeutic sensitivity of Lewis lung tumor. British Journal of Cancer 1977; 36: 105–113
   PubMed Web of Science ®Google Scholar
• Steel G. G., Nill R. P., Peckham M. J. Combined radiotherapy-chemotherapy of Lewis lung carcinoma. International Journal of Radiation Oncology, Biology and Physics 1978; 4: 49–52
   PubMed Web of Science ®Google Scholar
• Szekely J. G., Lobreau A. U., Delaney S. Morphological effects of lonidamine on two human-tumor cell culture lines. Microscopy 1989; 3: 681–693
   Web of Science ®Google Scholar
• Teicher B. A. Preclinical models for high dose therapy. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, J. O. Armitage, K. H. Antman. Williams & Wilkins, Baltimore 1992; 14–42
   Google Scholar
• Teicher B. A., Herman T. S., Holden S. A., Epelbaum R., Liu S., Frei E., III. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Cancer Research 1991a; 51: 780–784
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Herman T. S., Tanaka J., Dezube B., Pardee A., Frei E., III. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma. Cancer, Chemotherapy and Pharmacology 1991b; 28: 45–50
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Holden S. A., Herman T. S., Frei E., III. Modulation of alkylating agents by lonidamine in vivo. Seminars in Oncology 1991c; 18: 7–10
   PubMed Web of Science ®Google Scholar
• Teicher B. A., Jacobs J. L., Kelley M. J. The influence of Fluosol-DA on the occurrence of lung metastases in Lewis lung carcinoma and B16 melanoma. Invasion Metastasis 1988; 8: 45–56
   PubMedGoogle Scholar
• Tomirotti M., Bernardo G., Epifani C., Biasioli R., Franchi R., Mensi F., Carnaghi P., Schieppati G., Scanni A. Recovery of response to adriamycin and cyclophos-phamide by lonidamine in previously treated metastatic breast cancer patients. International Journal of Oncology 1993; 3: 213–217
   PubMed Web of Science ®Google Scholar
• Wondergem J., Bulger R. E., Siddik Z. H., Leygraaf J. W., Strebel F. R., Alonso M., Travis E. L., Bull J. M. C. A comparison of thermal enhancement of cis-diamminedichloro-platinum(II) induced renal and intestinal toxicities by whole body hypertherrmia in the rat. International Journal of Radiation Oncology, Biology and Physics 1989; 16: 1551–1556
   PubMed Web of Science ®Google Scholar
• Wondergem J., Bulger R. E., Strebel F. R., Newman R. A., Travis E. L., Stephens L. C., Bull J. M. C. Effects of cis-diamminedichloroplatinum(II) combined with whole body hyperthermia on renal injury. Cancer Research 1988a; 48: 440–446
   PubMed Web of Science ®Google Scholar
• Wondergem J., Strebel F. R., Siddik Z. H., Newman R. A., Bull J. M. The effects of anaesthetics on cis-platinum-induced toxicity at normal temperatures and during WBH: the influence of NaCl concentration of the vehicle. International Journal of Hyperthermia 1988b; 4: 643–654
   PubMed Web of Science ®Google Scholar
• Zaffaroni N., Bearzatto A., Gornati D., Silvestrini R. Effect of lonidamine on the cytotoxic activity of cisplatin, mitomycin C and BCNU in human ovarian and colon carcinoma cells. International Journal of Oncology 1994; 4: 773–778
   Web of Science ®Google Scholar